The F25 cohort marked a decisive shift from generic LLM wrappers toward deep infrastructure and hardware-integrated intelligence. Founders in this batch focused on solving the "last mile" of AI deployment, moving beyond chat interfaces to build embedded agents and high-precision physical perception systems for enterprise buyers who demanded production-ready reliability.
Traction was driven by a desperate need to eliminate the infrastructure tax associated with non-deterministic systems. Startups like Arcten and Efference succeeded by providing the specialized "visual cortex" and agentic middleware that allowed legacy industries to adopt AI without hiring massive engineering teams. They proved that willingness to pay was highest where AI solved high-stakes operational bottlenecks in robotics and capital management.
Many F25 startups eventually struggled as foundational model providers began absorbing the middleware layer into their core offerings. The core failure was over-investing in proprietary infrastructure that was quickly commoditized by open-source frameworks. Builders today must realize that bespoke orchestration is no longer a moat; the value has shifted entirely to proprietary data loops and vertical-specific execution.
The 2026 opportunity lies in building hyper-specialized, low-latency agents that operate on the edge or within highly regulated data silos. By leveraging modern small language models (SLMs), a solo builder can now recreate the complex workflows of F25 giants with a fraction of the compute, focusing on niche industrial automation where privacy and speed are the primary competitive advantages.
Platform to embed AI copilots into applications for executing complex workflows via natural language.
Intelligent stereo vision cameras with software-driven 3D perception for robots.
Financial operating system for real estate owners, offering banking, corporate cards, AI optimization, and compliance tools.
Affordable humanoid robots using artificial muscles to perform household chores at iPhone prices.
AI-powered platform that automates regulatory document preparation and consolidation for Investigational New Drug (IND) submissions in biotechnology.